Cara Therapeutics has updated its progress as of Q1 2016.

“We look forward to reinitiating our adaptive pivotal trial of I.V. CR845 for postoperative pain this month,” said Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer of Cara Therapeutics.

“We also remain on track to initiate our registration program for I.V. CR845 in hemodialysis patients suffering from uremic pruritus during the second quarter of 2016, and a Phase 2b trial of Oral CR845 in chronic pain in the second half of 2016. This will significantly expand our later-stage pipeline in indications in which we have already seen positive proof-of-concept data.”